AC Immune Q3 net loss narrows as revenue rises
ACIU•ACIU•ACIU•ACIU•AC Immune said third-quarter revenue rose, driven by revenue recognized under its Takeda arrangements, while net loss narrowed to CHF 8.75 million from CHF 15.9 million a year earlier. Loss per share was CHF 0.13.
AC Immune reported third-quarter revenue growth, attributing the increase to recognition of additional consideration under its Takeda arrangements. Net loss narrowed to CHF 8.75 million from CHF 15.9 million; operating expenses were CHF 13.05 million and operating loss was CHF 9.80 million.
The company expects further clinical data for ACI-7104 before year-end and ACI-19764 data in early 2027. It also expects ACI-7104 antibody characterization data before year-end 2026 and initial Phase 1b results for ACI-19764 in cardiovascular patients in early 2027. AC Immune highlighted FDA Fast Track status for ACI-7104.
Lower personnel and operational costs reduced research and development expenses, partly offset by higher clinical program spending. More favorable exchange differences improved the financial result.
